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ABSTRACT
The first 11 nt at the 5′ end of influenza virus genomic
RNA were shown to be both necessary and sufficient
for specific binding by the influenza virus poly-
merase. A novel in vitro transcription assay, in which
the polymerase was bound to paramagnetic beads
via a biotinylated 5′-vRNA oligonucleotide, was used
to study the activities of different forms of the
polymerase. Complexes composed of co-expressed
PB1/PB2/PA proteins and a sub-complex composed
of PB1/PA bound to the 5′-vRNA oligonucleotide,
whereas PB1 expressed alone did not. The enriched
5′-vRNA/PB1/PB2/PA complex was highly active for
ApG and globin mRNA primed transcription on a
model 3′-vRNA template. RNA synthesis in the
absence of added primers produced products with
5′-terminal tri- or diphosphate groups, indicating that
genuine unprimed initiation of transcription also
occurred. No transcriptase activity was detected for
the PB1/PA complex. These results demonstrate a role
for PA in the enhancement of 5′ end binding activity of
PB1, a role for PB2 in the assembly of a polymerase
complex able to perform both cap-dependent and
-independent synthesis and that NP is not required
for the initiation of replicative transcription.
INTRODUCTION
The influenza virus RNA polymerase is a multifunctional
complex composed of the three viral proteins PB1, PB2 and
PA, which, together with the viral nucleoprotein NP, form the
minimum complement required for viral mRNA synthesis and
replication (1). PB1 contains the polymerase active site for
nucleotide addition (2,3), the sites for sequence specific
binding to the conserved 5′ and 3′ terminal sequences of the
negative and positive sense viral RNAs (4,5) and independent
binding sites for the PB2 and PA polymerase subunits (6). PB2
binds to host cell capped mRNAs (7,8) and has been proposed as
the viral endonuclease responsible for cleavage of these RNAs to
form the primers for viral mRNA synthesis (9,10). However,
other data strongly indicate that PB1 is the endonuclease (11).
PB1 and PB2 also bind NP (12,13) and, while the function of
these P–NP interactions is unknown, they are apparent in an
electron-microscopic reconstruction of a recombinant mini-RNP
(14). Genetic evidence from temperature sensitive mutations in
the PA segment suggests that this protein may be involved in
the transition from mRNA transcription to cRNA and vRNA
synthesis (reviewed in 15). However, a clear role for PA in
RNA synthesis has yet to be defined.
The polymerase complex must synthesise three different viral
RNA species: viral mRNA; the cRNA replication intermediate;
and negative sense vRNA. The 5′ end of the viral mRNA is
composed of a cap structure and 10–15 nt derived from the host
cell mRNA, which are used as primers for initiation (16). mRNA
transcription terminates 15–17 nt before the end of the vRNA
template, at which point the RNA is polyadenylated (17).
cRNA is the full length complement of vRNA. The mechanism
of mRNA synthesis is relatively well understood (reviewed in
18) and quite distinct from that of v- and cRNA. Much of this
understanding has come from the use of in vitro systems for
studying the polymerase. One such system uses recombinant
vaccinia viruses to express the polymerase. This has provided
important insights into the composition and formation of the
active transcription complex (1,19,20). It has been used primarily
to study the early events of transcription such as template
binding, cap-binding and endonuclease activities. This work
forms the basis of the model for the ordered assembly of the
viral transcription complex responsible for mRNA synthesis
(21). Unfortunately the extracts used in this system contain a
substantial amount of ribonuclease activity that precludes its
use for studying transcriptional elongation, termination or
polyadenylation.
The mechanisms responsible for c- and vRNA synthesis
remain very poorly characterised. The 5′ terminal base of
vRNA and cRNA is adenosine triphosphate (22–24), which
implies that initiation does not involve the use of a capped primer
but is instead initiated de novo. It is not known if different forms
of the polymerase perform different transcriptional functions and
the precise subunit requirements for replicative transcription
remain a matter of controversy. Evidence for complexes of
PB1 and PA or even PB1 alone being capable of performing
some of the transcriptional activities associated with genome
replication (25,26) is contradicted by other studies that have
concluded that PB2 is an essential part of the polymerase
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complex for all forms of transcription (27).  The form of
polymerase packaged into virions is unable to synthesise
cRNA (28,29) and after infection an initial round of viral
mRNA synthesis and translation is required before cRNA
synthesis can occur (30). Although the involvement of host-
cell proteins has been proposed (31,32), it is likely that this
requirement for protein synthesis reflects the obligatory
synthesis of a viral protein (e.g. NP and/or polymerase) for
replicative transcription. Synthesis of a full-length cRNA requires
readthrough of the polyadenylation signal (anti-termination),
which in vitro, using infected cell extracts, is dependent upon
the availability of NP (33,34). Consistent with an essential role
for NP, several NP mutants have been isolated that are
selectively defective for c- and/or vRNA synthesis (15,35–38).
Two such mutants have RNA binding defects indicating that
an NP–RNA interaction may be required for the control of
replicative synthesis (13). Nevertheless, the precise role of NP
in replicative transcription remains unclear. In particular, it is
not known what causes the polymerase to swap from cap-primed
transcription initiation to unprimed synthesis and whether NP
is required for this step.
Here we report the identification of the minimal 5′-vRNA
oligonucleotide capable of being bound by recombinant
polymerase and its use as an affinity ligand to circumvent the
limitations of the vaccinia virus-expression system to allow the
transcriptional activities of a highly active recombinant
polymerase to be measured. We show for the first time that
transcription initiation in the absence of added primers,
in vitro, produces RNA products with the authentic terminal
structure expected for a true cRNA replicative intermediate
produced in vivo. Furthermore, whereas the PB2 protein is




Plasmid pMLV3′ contains the T7 promoter upstream of the 3′
terminal sequence of segment 8 of the A/PR/8/34 strain of
influenza virus. Plasmid pPH-V has been described previously
(19). It encodes a model pan handle template RNA composed
of the 5′ and 3′ ends of segment 8 separated by a short linker.
Rabbit antisera against C-terminal peptides of PB1, PB2, PA,
monoclonal antibody (10.2) specific for PB1 and polyclonal
serum raised against amino acids 50–370 of PB1 (anti-PB1-F1)
have been described previously (6,19). Hyperimmune poly-
clonal anti-PB2 serum (anti-MBP-2N580) was raised in rabbits
using a maltose-binding protein fusion polypeptide containing
amino acids 580–759 of PB2. Polyclonal anti-PA sera were
raised in rabbits (6) with bacterially expressed β-galactosidase
fusion proteins containing amino acids 16–213 (anti-PA-F2) or
187–340 (anti-PA-F3) of A/PR/8/34 PA.
Virus and cell culture
Recombinant vaccinia viruses that individually express the
three influenza virus RNA polymerase proteins (VacPB1,
VacPB2 and VacPA) (39) or express the T7 RNA polymerase
protein (VTF 7.3) (40) were propagated on HeLa cell mono-
layers and titrated on BSC-1 cells using standard procedures (41).
Preparation of virus infected cell extracts
Nuclear extracts from vaccinia-infected HeLa cells were
prepared as previously described (42,43). Briefly, HeLa cells
grown as monolayers on 800 cm2 roller bottles were infected
with the recombinant vaccinia viruses that express PB1, PB2
or PA (m.o.i. = 5 for each virus, for triple, double or single
infections) or T7 RNA polymerase (m.o.i. = 10). Cells were
harvested 18 h post infection and lysed in hypotonic buffer
containing 0.2% Nonidet P-40. The nuclei were recovered,
lysed in buffered 0.3 M ammonium sulphate and soluble
nuclear proteins precipitated by raising the concentration of
ammonium sulphate to 1.5 M. Precipitated proteins were
redissolved in 50 mM HEPES pH 7.6, 50 mM KCl, 0.1 mM
EDTA, 1mM dithiothreitol (DTT) at ∼10 mg/ml and stored in
small aliquots at –70°C. The presence (or absence) of the
expected P proteins in the extracts was confirmed by western
blot analysis (data not shown).
Synthesis of template RNAs and RNA probes
Plasmids pPH-V and pMLV3′ were linearised with MboII and




GCU-3′, respectively, where the underlined letters correspond
to the conserved 5′ and/or 3′ terminal vRNA sequences. The
transcripts were purified by electrophoresis through 18%
polyacrylamide gels containing 7 M urea. The RNA bands
were located by UV shadowing, excised and recovered by
passive elution into 1 mM EDTA. The RNAs were then
ethanol precipitated and quantitated using the Ribogreen™
assay (Molecular Probes Inc.). Radiolabelled RNAs were
prepared by phosphorylation of the 5′ end of the RNA transcripts
using polynucleotide kinase (Boehringer Mannheim, Indianapolis,
IN) and [γ-32P]ATP (3000 Ci/mmol) and were repurified as
described above. A synthetic RNA oligonucleotide (5′V16B)
was synthesised (Cruachem Ltd) with the sequence: 5′-AGU-
AGAAACAAGGGUG(CH2)12-biotin.
Defining the minimal length requirements for 5′ end binding
5′ end labelled PHV RNA (~5 × 106 c.p.m.) was subjected to
partial alkaline hydrolysis to produce a probe mixture
comprised of nested 5′ co-terminal labelled RNAs. The hydro-
lysis reaction was terminated by adding sufficient 0.1 N
hydrochloric acid to neutralise the sample. Binding reactions
(20 µl) containing 5 × 105 c.p.m. of probe RNA and 20 µg of
nuclear extract were prepared as described above. The samples
were then centrifuged through 10–20% w/v sucrose gradients
at 37 000 r.p.m. (164 000 g) for 18 h at 3°C using a Beckman
SW50.1 rotor as described previously (19). Fractions (200 µl)
were collected drop-wise from the bottom of the tube. Aliquots
of 10 µl from each fraction were analysed in a scintillation
counter to determine the migration of the probe RNA. 2000 c.p.m.
from the bound and free peaks on the gradient were then
analysed on a 20% 7 M urea sequencing gel and compared to
the original hydrolysis ladder, and to an RNA sequencing
ladder produced using an RNA sequencing kit (Pharmacia
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Affinity purification of the polymerase and in vitro 
transcription reactions
Streptavidin coated paramagnetic beads (SA-beads, Dynal,
M280) were prepared by washing twice with 0.1 M NaOH/
50 mM NaCl, once with 100 mM NaCl and once with minimal
binding buffer (MBB: 10 mM HEPES pH 7.5, 0.5 mM EGTA,
2 mM MgCl2, 120 mM KCl, 10% glycerol) + 0.1% BSA and
then resuspended in MBB. SA-beads, 5 µl per reaction, were
incubated with 1 pmol of the biotinylated RNA oligonucleotide
(5′V16B) in 10 µl 50 mM Tris pH 7.5, 0.5 mM EDTA, 1 M
NaCl (TEN buffer) at room temperature for 10 min to allow
binding of the oligonucleotide to the SA-beads. The reaction
was washed twice with TEN buffer and once with MBB. The
SA-beads were finally resuspended in 10 µl complete binding
buffer (10 mM HEPES pH 7.5, 0.5 mM EDTA, 1.8 mM
MgCl2, 120 mM KCl, 10% glycerol, 10 U RNasin, 1 mM DTT)
containing 10 µg of nuclear extract and incubated at room
temperature for 15 min. The SA-beads were then washed twice
with 100 µl MBB. Samples for western blotting and silver
staining experiments were resuspended in 1× SDS–PAGE
loading buffer. Samples intended for transcription reactions
were resuspended in 10 µl transcription buffer containing the
appropriate primer, nucleotides and template. Typical reaction
conditions were 50 mM Tris pH 8.2, 100 mM KCl, 2 mM MgCl2,
100 ng tRNA, 10 mM DTT, 10 pmol 3′V template, 5 µCi [α-
32P]GTP (400 Ci/mmol; Amersham Pharmacia Biotech Ltd),
0.8 mM ATP, 0.4 mM CTP, 0.2 mM UTP, 1 µM GTP and
0.5 mM ApG or 20 ng globin mRNA (Gibco-BRL). Reactions
were incubated at 30°C for 30 min and terminated by adding 10 µl
of RNA loading dye mix (80% formamide, 0.2× TBE, 0.05%
bromophenol blue, xylene cyanol, Orange G). Transcription
products were resolved by electrophoresis on an 18% (19:1
acrylamide:bisacrylamide) 7 M urea gel maintained accurately
at 55°C using a heat exchanger and visualised by autoradio-
graphy at –70°C without prior drying of the gel. Exposure
times ranged from 16 to 120 h as indicated in the figure
legends.
Gel shift assays
Assays were performed as described previously (19). Binding
reactions of 10 µl contained 1–2 × 104 c.p.m. of RNA probe
and 10 µg of nuclear extract. The final buffer components
were: 20 mM HEPES pH 7.6, 0.5 mM EGTA, 20 µM EDTA,
2 mM MgCl2, 7.5 mM NaCl, 110 mM KCl, 1.2 mM DTT,
27.5 µg/ml RNase free BSA (Boehringer Mannheim), 1 U/µl
RNAGuard (Pharmacia) and 12% glycerol. Binding reactions
were incubated at room temperature for 30 min and terminated
by the addition of heparin (Sigma Chemical Co.) to a final
concentration of 5 mg/ml. Complexes were resolved by native
gel electrophoresis (4%; 79:1 acrylamide:bis acrylamide, 50 mM
Tris–HCl pH 8.4, 50 mM glycine, 3% glycerol, 12 V/cm), and
visualised by autoradiography.
SDS–PAGE and western blot analysis
Samples from total nuclear extracts or SA-bead purified
polymerase were resuspended in SDS–PAGE loading buffer
containing 10% 2-mercaptoethanol, boiled for 5 min and then
analysed by discontinuous PAGE (4.5% stacking gel and 7.5%
resolving gel). Resolved proteins were visualised by silver
staining (Silver Stain Plus, Bio-Rad Laboratories). For western
blots, proteins were transferred to PVDF or nitrocellulose
membranes (Amersham Life Science or Schleicher and Schuell,
respectively) by semi-dry electroblotting (Bio-Rad Laboratories).
Membranes were probed with antisera as indicated in the figure
legends. Bound antibodies were detected using biotin conjugated
goat, anti-rabbit or anti-mouse IgG secondary antibody as
appropriate (Sigma-Aldrich Co.) followed by either streptavidin
conjugated alkaline phosphatase/BCIP/NBT development
(Sigma-Aldrich Co.) for Figure 2 only; or streptavidin conjugated
horseradish peroxidase (Pierce) chemiluminescent development
according to the manufacturer’s protocol (BM Chemiluminescence
Blotting substrate, Roche Diagnostics Ltd).
Analysis of 5′ end groups
Standard transcription assays were scaled up proportionately to
200 µl for unprimed synthesis or 80 µl for ApG, GpppG and
globin mRNA primed synthesis. The reactions were performed
as described above except that UTP was omitted from the
reaction mixture to prevent the polymerase from transcribing
beyond nucleotide 13 of the 3′V template (first A occurs at
position 14). The reactions were terminated by addition of an
equal volume of phenol/chloroform, phenol extracted and
ethanol precipitated twice from 2.5 M ammonium acetate to
reduce NTP levels. Each sample was finally redissolved in
20 µl of water. Five microlitres of each sample was then
treated with 3 U of calf intestinal phosphatase (CIP; Roche
Diagnostics Ltd) or tobacco acid pyrophosphatase (TAP; Epicenter
Technologies) (44) for 1 h at 50 or 37°C, respectively, in the
reaction buffers supplied with the enzymes. For analysis using
guanylyl transferase (GTase) it was necessary to disrupt the
RNA/RNA duplex formed by the template 3′-vRNA and the
5′-cRNA product RNA. The samples were prepared as
described above, except that after ethanol precipitation the
samples were redissolved in GTase reaction buffer (50 mM
Tris–HCl pH 7.9, 1.2 mM MgCl2, 6 mM KCl) incubated with
a 30-fold excess of biotinylated 5′-cRNA oligonucleotide at
80°C for 2 min and then cooled to 37°C to allow the RNA to
anneal to the 3′-vRNA template RNA. The samples were then
incubated with SA-beads to remove the annealed RNAs. The
samples were supplemented with 3 mM DTT, 2 U RNasin and
GTase (45), and incubated for 2 h at 37°C. To avoid any
possible electrophoresis artifacts due to differences in the
reaction components, mock treated controls were incubated
under identical conditions in the absence of the enzyme for
each sample. All reactions were terminated by the addition of
80% formamide/1 mM EDTA RNA loading buffer and heated
to 90°C for 2 min. The reaction products were analysed by 7 M
urea, 18% PAGE as described above.
RESULTS
Definition of a minimal length 5′-vRNA sequence for 
polymerase binding
Mutational and modification interference analysis of the 5′-vRNA
sequence has defined the specific bases required for binding by
the polymerase. Nucleotides A1, G2, U3, A8, C9, A10 and
A11 of the wild-type sequence are involved in binding, either
directly or through short range interactions, to form a hooked
RNA secondary structure (19,46–49). However, it remained to
be demonstrated what constituted the minimal polymerase432   Nucleic Acids Research, 2002, Vol. 30, No. 2
binding region on the RNA and whether any non-base-specific
interactions outside this region were involved. To this end, a
synthetic 5′ end-labelled vRNA was subjected to partial alkaline
hydrolysis to generate a nested set of 5′ co-terminal labelled
RNAs that run as a ladder of products on a denaturing gel
(Fig. 1, lane 5). This population of RNAs was incubated with
sufficient Vac3P nuclear extract to bind ∼30% of the input
RNA and bound and free populations of RNA separated by
sucrose gradient centrifugation. Under the conditions used,
binding is specific, and no complex was detected for control
extracts lacking the polymerase (19). RNA remaining at the top
of the gradient was almost totally degraded by the nucleases
present in the extract (Fig. 1, lane 6). However, RNA that
migrated through the gradient to the position associated with
the 3P polymerase (Fig. 1, lane 7) was not degraded, as
evidenced by the predominant band corresponding to the full
length RNA and the distribution of smaller RNAs corresponding
to alkaline hydrolysis products that were still able to bind to the
polymerase. RNAs below a certain size no longer bound and
the cut-off point could be identified by comparison with the
corresponding sequencing ladder (Fig. 1, lanes 1–3, migration
of the bound RNA was altered slightly by the presence of
sucrose from the gradient). This showed that RNAs including
at least the region from the 5′ end to base A11 of vRNA bound
to the polymerase but smaller fragments of the 5′-terminus did
not. The presence of a band corresponding to G2 in the bound
fraction (Fig. 1, lane 7) may indicate an affinity of the
polymerase for ApG, but is most likely explained as a trace
contaminant from the abundant G2 degradation product found
in the free population (Fig. 1, lane 6). The smallest fragment of
vRNA bound by the polymerase contains all the bases
previously shown to be critical for polymerase binding (19,46)
thus demonstrating that no other RNA contacts outside this
region are necessary for this interaction.
Identification of polymerase subunits required for 5′ end 
binding
The polymerase packaged into influenza virions consists of
one copy each of the three P proteins (50), but it is less clear if
a trimeric polymerase is the minimal functional unit in infected
cells (25,26). Previous studies on recombinant polymerase
in vitro demonstrated that co-expression of all three P proteins
was necessary to form an enzymatically active complex
(9,19,20). Analysis of template binding activity by gel shift
assays combined with P-specific antibody supershifts
confirmed the presence of PB1 and PB2 in the complex, but
failed to show the presence of PA (19). This was attributed to
the PA antibodies being unable to bind PA under the native
conditions used in the assay. To overcome this limitation, an
alternative strategy was used where the RNA/protein
complexes were recovered and the protein component
analysed by western blot, for which there are many suitable
antibodies. To facilitate recovery of P-protein/RNA complexes, a
short RNA molecule containing the essential 5′-vRNA binding
site was bound to streptavidin-coated paramagnetic beads
(SA-beads) via a 3′ terminal biotin group. The SA-beads were
then incubated with nuclear extracts containing the P proteins
or T7 RNA polymerase as a negative control. After thorough
washing, the bound polypeptides were analysed by western
blotting using antibodies to PB1, PB2 or PA (Fig. 2). All three
P proteins were detected in the total Vac3P extract, but not in
the negative control VacT7 extract (Fig. 2, lanes 5 and 6). The
recombinant P proteins were seen to co-migrate with the
authentic P proteins in purified A/PR/8/34 virions (lanes 5 and 7),
Figure 1. Defining the minimum length 5′ end binding site for the influenza
polymerase. 5′ end labelled PHV RNA was subjected to limited alkaline
hydrolysis to produce a ladder of labelled 5′ co-terminal RNA species (lane 5).
5 × 105 c.p.m. of hydrolysed RNA was mixed with Vac3P extract and bound
and free populations separated by sucrose gradient centrifugation. Equal amounts
of RNA from the bound and free peaks were then analysed on a 7 M urea, 20%
acrylamide gel. Lanes 1–3, RNA sequencing ladder using base-specific ribo-
nucleases T1 (G), U2 (A) and B.cereus (U/C). Lane 4, untreated RNA. Lane 6,
free (non-bound) RNA. Lane 7, bound RNA.
Figure 2. Composition of the P protein complex bound to 5′-vRNA. Nuclear extracts
from Vac3P or VacT7 infected HeLa cells were incubated with a biotinylated RNA
oligonucleotide containing the conserved 5′ terminal sequence of vRNA bound
to streptavidin coated paramagnetic beads. Bound proteins were then analysed
by western blot using C-terminal peptide antibodies specific for (A) PB1,
(B) PB2 and (C) PA. Lane 1, 5′-vRNA coated SA-beads incubated with Vac3P
extract. Lane 2, 5′-vRNA coated SA-beads incubated with VacT7 extract.
Lanes 3 and 4, uncoated SA-beads incubated with Vac3P or VacT7 extracts,
respectively. Lane 5, total Vac3P extract. Lane 6, total VacT7 extract. Lane 7,
purified A/PR/8/34 virus marker.Nucleic Acids Research, 2002, Vol. 30, No. 2   433
although in this experiment the antipeptide antiserum to the C-
terminus of PB2 reacted poorly with the A/PR/8/34 sample
(Fig 2, lane 7). Cross reactivity of the anti-PA serum with an
unidentified polypeptide with slightly slower electrophoretic
mobility than PA was also noted (Fig. 2C, lanes 5 and 6). No
detectable binding of the P proteins to the SA-beads was observed
in the absence of the biotinylated 5′-vRNA oligonucleotide
(Fig. 2, lane 3). However, in the presence of the 5′-vRNA
sequence, PB1, PB2 and PA all bound to the SA-beads (Fig. 2,
lane 1). This confirms that PA is indeed a component of the
binding complex(es) present in the nuclear extracts.
PB1 has been shown by cross-linking and northwestern blot
analysis to be the protein most directly involved in 5′ end
binding (4,51), but other experiments suggest that all three
P proteins play a role (19,20,52). The minimum complement
of P proteins required for binding to a model panhandle vRNA
was determined using a gel-shift assay with extracts prepared
from cells infected with pair-wise combinations of P proteins.
Binding of a protein complex to the RNA causes the migration
of the probe RNA to be retarded. A slower migrating complex
was observed when the probe was incubated with extracts from
Vac3P or VacPB1/PA infected cells (Fig. 3A, lanes 1 and 4).
The extract containing only PB2 and PA did not cause retardation
of the RNA probe significantly above that seen for the control
extract (Fig. 3A, lanes 5 and 6). This is consistent with a major
role for PB1 in template binding. However, extracts containing
PB1 alone, or PB1 and PB2 also did not bind (Fig. 3A, lanes 2
and 3). This implies that both PB1 and PA are required for
template binding. The 3P complex and the PB1/PA complex
had very similar electrophoretic mobilities, although it might
have been expected that the 3P complex containing PB2 would
migrate more slowly. The presence or absence of PB1, PB2
and PA in the appropriate extracts and complexes was
confirmed by western blot and antibody supershift experiments,
respectively (data not shown). Because none of the available
antibodies against PA caused super-shifting, further confirmation
of the composition of the complexes was therefore obtained
using the SA-bead binding assay. The results were in complete
agreement with those from the gel shift assay. No binding of P
proteins was observed with extracts containing PB1 alone,
PB2 and PA, or PB1 and PB2 (Fig. 3B, lanes 3, 4 and 6). In
contrast, when PB1 and PA were co-expressed, either with or
without PB2, both proteins bound to the RNA-coated SA-beads
(Fig. 3B, lanes 1 and 5). We therefore conclude that PA is
required for efficient binding of PB1 to the 5′-terminus of
vRNA.
Affinity purification of RNA polymerase using a synthetic 
RNA ligand
The ability of the polymerase to bind stably to short RNA
molecules containing the 5′-vRNA terminal sequences bound
to a solid matrix presented an avenue for selective enrichment
of the polymerase. To assess the degree of purification,
proteins that bound the immobilised 5′-vRNA were analysed
by SDS–PAGE and silver staining. Comparison between the
unfractionated Vac3P and VacT7 extracts (Fig. 4A, lanes 4 and
5) demonstrated that the proportion of P protein to total protein
was low, with no identifiable P-specific polypeptides in the
Vac3P extract. Analysis of material bound to the 5′-vRNA-coated
SA-beads showed a selective enrichment of the polymerase
such that polypeptides of the expected molecular weights for
PB1 and PB2/PA (PB2 and PA co-migrate in this gel system)
were now clearly visible in the Vac3P but not the VacT7
extract (Fig. 4A, lanes 1 and 3, respectively). Parallel western
blot analysis with anti-PB1 and -PB2 sera showed that these
polypeptides co-migrated with PB1 and PB2, respectively
(Fig. 4B and C, lanes 1). Heparin is known to inhibit binding of
the polymerase to the 5′ end of vRNA, although it does not
efficiently displace polymerase that has already bound (19).
Inclusion of heparin in the binding reaction strongly inhibited
binding of the polymerase to the SA-beads but did not substantially
alter the binding of the background polypeptides (Fig. 4A–C,
lanes 2) indicating that they are not bound to the bead through
any affinity for the polymerase itself. In addition, binding of
the polymerase (PB1) to the immobilised 5′ end could be
inhibited completely by a 20-fold excess of a panhandle RNA
containing the 5′-vRNA sequence, thus confirming the specificity
of the interaction (Fig. 4D, lane 7). To determine the approximate
amount of polymerase that bound to the bead, a comparison
was made between the amount of bound PB1 and a titration of
virion associated PB1. Based on the estimate that each P protein
comprises ∼1% of the total protein in virions (53), ∼5 ng of PB1
bound to the SA-beads (Fig. 4D, lane 8). This is a small fraction of
the PB1 present in the total extract (∼75 ng; Fig. 4D, lane 1).
Transcriptional activity of the immobilised polymerase
The sequence of the oligonucleotide used for the affinity
purification was deliberately chosen to include four bases 3′ to
the minimal binding site defined in Figure 1. This was done for
two reasons. First, it was possible that the physical proximity
of the SA-bead relative to the polymerase binding sequence
could cause steric problems. Extending the sequence by a few
bases would allow more flexibility for binding. Secondly,
these additional bases are known to be crucial for efficient
transcription of template RNAs, where they are probably involved
in 3′ template recognition and binding (47,54). Therefore, by
including these sequences, it was realistic to expect that the
Figure 3. Binding of polymerase sub-complexes to 5′-vRNA sequences. (A) Gel
shift analysis of polymerase sub-complexes. Nuclear extracts (10 µg total protein)
from cells infected with vaccinia viruses expressing the indicated proteins
were incubated with radiolabelled PHV RNA and analysed by non-denaturing
gel electrophoresis. The migration of the bound and the free probe is indicated.
(B) 5′-vRNA bound to SA-beads was incubated with nuclear extracts (5 µg
total protein) from HeLa cells infected with: Vac3P (lane 1), VacT7 (lane 2),
VacPB1 (lane 3), VacPB2 + VacPA (lane 4), VacPB1 + VacPA (lane 5) and
VacPB1 + VacPB2 (lane 6). Bound proteins were resolved by SDS–PAGE and
analysed by chemiluminescent western blotting using antibodies specific for
the individual P proteins as indicated (PB1, monoclonal antibody 10.2; PB2,
anti-MBP-2N580; PA, 1:1 mixture of anti-PA-F2 and anti-PA-F3). Lane 7,
purified A/PR/8/34 virus marker.434   Nucleic Acids Research, 2002, Vol. 30, No. 2
polymerase might be transcriptionally active while still bound to
the SA-bead. In addition, enrichment of the polymerase should
reduce the level of nucleases that prevented transcriptional
activity of the vaccinia virus-expressed polymerase from being
studied satisfactorily in the past. To test this, the bound
polymerase was resuspended in transcription buffer containing
ribonucleotides, [α-32P]GTP, a 34 nt in vitro transcribed RNA
containing the 3′-terminal sequence from A/PR/8/34 segment
8 vRNA, and either ApG, globin mRNA (as a model cellular
capped RNA) or no primer. After incubation at 30°C for
30 min the reaction products were analysed by denaturing
PAGE. ApG primed transcription produced a major reaction
product 34 nt long that corresponds to the predicted full-length
transcription product for the template used in this assay
(Fig. 5A, lane 1 and 5B, lane 2). In contrast, no full-length
products were synthesised by the 3P nuclear extract incubated
with the same reaction components if the polymerase enrichment
step was omitted (Fig. 5B, lane 8), providing a clear illustration
of the improvement this new assay represents. Reactions
primed with globin mRNA gave rise to a longer product of
∼46 nt as expected for a full length product containing an
additional 12 globin mRNA derived bases and cap-structure at
the 5′ end (Fig. 5A, lane 2 and 5B, lane 3). Synthesis of these
products was dependent on the inclusion of polymerase,
biotinylated 5′ vRNA and 3′ template as omission of any single
component ablated activity (Fig. 5A, lanes 3, 4 and 7).
Significantly, low level synthesis of two specific products
was also observed in the absence of added primer (Fig. 5B,
lane 1 with lane 4 serving as a control). One transcription
product migrated slightly faster than the 34 nt ApG primed
product (Fig. 5B, compare lanes 1 and 2). This is consistent
with the increased electrophoretic mobility expected for an
RNA with a 5′-triphosphate characteristic of unprimed replic-
ative synthesis initiated with ATP (ApG-primed synthesis
gives rise to a 5′-hydroxyl). A second product of the predicted
size for mRNA primed transcripts (~46 nt) was also observed
in the absence of added primer (Fig. 5B, lane 1) suggesting that
some capped mRNA-primed transcription might be occurring
even though no exogenous primer had been added. One explan-
ation for this is that there are low levels of capped RNAs
present in the nuclear extract that associate with the
polymerase after it has bound to the immobilised 5′ end and
can function as primers. Several diffuse background bands
were observed even in the absence of influenza virus
polymerase, primer, 5′-vRNA or template (Fig. 5A, lanes 3–7)
and are not considered to be significant. However, a prominent
group of prematurely terminated influenza virus specific
Figure 4. Selective enrichment of influenza virus RNA polymerase using
immobilised 5′-vRNA oligonucleotide. (A) Nuclear extracts from Vac3P or
VacT7 infected HeLa cells were analysed by SDS–PAGE and silver stained
before or after binding to SA-beads coated with the 5′vRNA oligonucleotide in
the presence or absence of 5 mg/ml heparin (Hep) as indicated. Identities of the
protein bands were determined by comparison between silver stained gel and
duplicate western blots probed with antibodies specific for PB1, anti-PB1-F1
(B) or PB2, anti-MBP-2N580 (C). Lane 1, Vac3P incubated with SA-beads
coated in 5′-vRNA. Lane 2, Vac3P in the presence of 5 mg/ml heparin
incubated with SA-beads coated in 5′-vRNA. Lane 3, VacT7 incubated with
SA-beads coated in 5′vRNA. Lane 4, crude Vac3P extract. Lane 5, crude
VacT7 extract. (D) Estimation of the quantity of PB1 bound to the immobilised
vRNA oligonucleotide. Vac3P nuclear extract was analysed by SDS–PAGE
and western blotting with anti-PB1 MAb 10.2 before (lane 1, T) or after binding to
RNA-coated SA-beads in the presence (lane 7, +PH) or absence (lane 8, B) of
a non-biotinylated competitor panhandle RNA in parallel with a dilution series
of purified A/PR/8/34 virions (lanes 2–6). Also indicated are the approximate
quantities of PB1 present in each virion sample.
Figure 5. Immobilised affinity purified polymerase is transcriptionally active.
Nuclear extracts from Vac3P or VacT7 infected HeLa cells were mixed with
SA-beads coated with the 5′-v16B oligonucleotide. The SA-beads were then
resuspended in transcription buffer containing nucleotides, the indicated
primer and 3′-vRNA template. Transcription products incorporated [α- 32P]GTP
and were resolved on an 18% 7 M urea denaturing polyacrylamide gel and
visualised by autoradiography for (A) 16 or (B) 120 h. (A) Lane 1: ApG
primed reaction. Lane 2, globin mRNA primed reaction. Lane 3, ApG primed
reaction with the omission of the 5′-v16B oligonucleotide. Lane 4, ApG
primed reaction with the omission of 3′V template RNA. Lane 5, unprimed
reaction. Lane 6, globin mRNA primed reaction using VacT7 nuclear extract.
Lane 7, ApG primed reaction using VacT7 extract. (B) Co-expression of PB2
is required for unprimed, ApG primed, globin mRNA primed transcription.
Lanes 1–3, SA beads coated with Vac3P. Lanes 4–6, SA beads coated with
VacPB1/PA. Lane 7, SA beads coated with VacT7. Lane 8, Vac3P extract plus
5′-v16B (omitting bead selection procedure). Lanes 1 and 4, unprimed
transcription. Lanes 2, 5, 7 and 8, ApG primed transcription. Lanes 3 and 6,
globin mRNA primed. Lane 4, VacPB1/PA, unprimed synthesis.Nucleic Acids Research, 2002, Vol. 30, No. 2   435
transcription products, most notably ~14 nt were obtained in
ApG primed reactions, although interestingly, not in those
primed with globin mRNA (Fig. 5A, lanes 1 and 2 and 5B,
lanes 2, 3 and 8).
PB2 is essential for in vitro transcription activity
There is some evidence that polymerase complexes lacking
PB2 have residual transcriptional activity (25,26). Having
shown that complexes of PB1 and PA are able to bind
efficiently to the 5′ end of vRNA (Fig. 3), the same extracts
containing incomplete combinations of P proteins were
analysed for their transcriptional activity. As expected, no
activity was detected from combinations lacking PB1 and/or
PA (data not shown). However, despite the substantial level of
vRNA binding activity present in the PB1/PA extract shown in
Figure 3, no significant transcriptional activity was detected for
either ApG, mRNA or unprimed reactions (Fig. 5B, lanes 4–6).
No bands of the predicted sizes were observed and any trace
products were also present in the T7 control (Fig. 5B, lane 7).
Therefore, we conclude that PB2 is an essential component of
the polymerase complex for all forms of transcription in vitro.
Characterisation of the unprimed transcription products
To confirm the identity of the two species of products observed
in unprimed transcription reactions, it was necessary to
examine the nature of their 5′ ends. Unprimed synthesis is
expected to produce a product with a 5′-terminal adenosine
triphosphate, ApG primed synthesis would have a 5′ hydroxyl,
and mRNA primed products would have a terminal m7GpppG
cap structure. These can readily be distinguished by the
differential effects of treatment with CIP, GTase and TAP. CIP
enzyme removes the 5′ phosphate of polynucleotides, leaving
a 5′ hydroxyl that causes the RNA to migrate slightly more
slowly on PAGE. GTase catalyses the transfer of GMP from
GTP onto RNA possessing a 5′ di- or triphosphate group (55),
thus decreasing the mobility of the product. TAP removes the
5′ capping G residue, increasing the electrophoretic mobility of
the RNA. It also hydrolyses 5′ nucleotide triphosphates to the
monophosphate (44). To maximise the changes in relative
mobility of the RNA products, transcription reactions were
modified by omitting UTP. This causes transcription to terminate
when the polymerase encounters the first adenine base at
position 14 in the template, thus producing a 13 nt product that
can be more readily resolved. This also rules out the possibility
that the product being analysed is merely a small fraction of the
input (34 nt) template RNA that has been labelled by some
spurious mechanism. Under these conditions, the 13 nt product
of unprimed transcription clearly migrated faster than the
major product of ApG primed transcription (Fig. 6A, lanes 1
and 5). Treatment with CIP altered the migration of this RNA
such that it now co-migrated with the ApG primed product that
was itself left unaffected by CIP treatment (Fig. 6A, lanes 2
and 6). This confirmed that the major product synthesised in
the absence of added primer has a 5′ terminal phosphate group.
Migration of the 13 nt product of unprimed transcription was not
affected by TAP treatment (Fig 6A, lane 4) because 5′ triphosphate
and monophosphate RNA oligonucleotides are not resolved
under these conditions (data not shown). Therefore, to examine
the number of 5′ phosphate groups present on the 13 nt
unprimed transcription product we tested the effect of GTase
treatment. A substantial fraction of the product migrated more
slowly after incubation with GTase (Fig 6B, lanes 3 and 4),
consistent with the addition of a capping guanosine residue. In
contrast, no shift in mobility was observed for the ApG primed
product (Fig. 6B, lanes 1 and 2). Therefore unprimed synthesis
by the polymerase gives rise to a product that contains a 5′ di- or
triphosphate group. Unprimed transcription also gave rise to a
larger product that was potentially the result of priming with
host cell mRNAs present in the nuclear extracts. Consistent with
this, under the UTP-deficient transcription reaction conditions
these minor transcription products resolved into several distinct
bands, as would be predicted for priming by a heterogeneous
mixture of host cell mRNAs (indicated by asterisk, Fig. 6A,
lanes 1–4). Furthermore, while treatment with CIP did not
affect these RNAs (Fig. 6A, lane 2), TAP treatment increased
their electrophoretic mobility as predicted for the removal of
Figure 6. Analysis of the 5′ terminal groups of the product RNAs. Transcription was performed in the absence of UTP to stall the polymerase at position 14 of the
template. The reaction products were recovered by phenol extraction and ethanol precipitation, resuspended in the appropriate buffer and incubated in the presence
(+) or absence (–) of CIP, TAP or GTase as indicated. The reaction products were then analysed by denaturing electrophoresis using 7 M urea 18% PAGE. The
bands corresponding to the major 13 nt unprimed product and mRNA primed products (*) are indicated. (A) Lanes 1–4, transcription in the absence of any added
primer. Lanes 5–8, ApG primed transcription. Lanes 9–12, unprimed transcription in the presence of 0.4 mM m7GpppG. Lanes 13–16, globin mRNA primed
transcription. (B) Product RNAs from ApG (lanes 1 and 2) or unprimed reactions (lanes 3 and 4) were prepared as above and depleted of template RNA as
described in the Materials and Methods. The samples were then treated with GTase (lanes 2 and 4) or mock treated (lanes 1 and 3) and analysed by PAGE as above.436   Nucleic Acids Research, 2002, Vol. 30, No. 2
the  m7GDP group (Fig. 6A, lane 4). TAP treatment of the
globin mRNA primed product similarly confirmed that it
possessed a 5′ terminal cap structure (Fig. 6A, lanes 15 and 16),
as did two larger, minor products of the transcription reaction.
CIP treatment did not alter the migration of these products, but
did however affect a minor RNA species that co-migrated with
the 13 nt major unprimed transcription product (Fig. 6A,
lanes 13 and 14). This RNA is probably the result of unprimed
transcription initiation occurring even in the presence of a
donor mRNA. However, another possible explanation is that it
corresponds to the 3′ endonucleolytic fragment of a globin
mRNA primed product that has subsequently been rebound
and cleaved by the polymerase (56), as this would be expected
to have a 5′ monophosphate. The same argument could also be
applied to the fraction of the 13 nt product obtained in the
absence of exogenous primer that was not capped by GT
(Fig. 6B, lane 4). This is unlikely, given the low level of
capped products present in the unprimed reactions and the very
different ratios of capped to uncapped products obtained
between unprimed and globin mRNA primed reactions
(Fig. 6A, lanes 1 and 13). In addition, control experiments
indicated that GTase mediated capping reactions proceed
inefficiently under the conditions used here because of the
formation of RNA duplexes between product and template
(data not shown). Nevertheless, to test the possibility that the
polymerase was endonucleolytically cleaving its own mRNA
products, we examined the effects of adding a large excess of
free cap analogue to the transcription reactions to compete out
polymerase binding to capped RNA oligonucleotides. The
addition of 0.4 mM m7GpppG completely abolished synthesis
of the ∼25 nt TAP sensitive capped RNA products (Fig. 6A,
lanes 9–12). However, a 13 nt CIP sensitive species was still
synthesised (Fig. 6A, lanes 9 and 10). This strongly suggests
that this RNA is not derived from cleavage of previously
synthesised viral mRNAs but instead is an authentic product
resulting from unprimed transcription initiation. Curiously,
reactions containing m7GpppG also gave rise to a product that
co-migrated with the major ApG primed RNA (Fig. 6A, lane
9). However, this RNA species was insensitive to TAP and CIP
treatment (Fig. 6A, lanes 7 and 8), indicating that it is not
capped or 5′-phosphorylated and is therefore most plausibly
the result of a contaminant in the m7GpppG preparation,
possibly GpG.
DISCUSSION
Expression of influenza virus RNA polymerase using vaccinia
virus vectors has been key to elucidating the template-binding,
cap-binding and endonuclease activities of the polymerase
(1,19–21,39,57). However, because the extracts contain significant
levels of nuclease activity they have not been suitable for
studying the transcriptional activities of the polymerase. This
limitation has now been overcome by the development of a
novel assay system that uses the affinity of the enzyme for the
conserved 5′-terminal sequences of the viral genome to purify
it away from the deleterious nucleases. An important advantage
this strategy has over conventional purification approaches is
that the polymerase is purified by virtue of one of its functional
properties, namely template binding. Previous studies using
polymerase expressed from heterologous systems have shown
that the polymerase has a tendency to form a wide spectrum of
complexes ranging from monomers to higher order aggregates
(6,52). The inclusion of an activity-based affinity purification
step is an effective way to remove non-functional polymerase
molecules. Repetitive depletion experiments using the SA-beads
have shown that the majority of the transcriptionally active
polymerase that is able to bind to the beads does so during the
first round (data not shown). We estimate that <10% of the
Vac3P polymerase is transcriptionally active. Although the
bead enrichment is very significant from a qualitative aspect
(i.e. in terms of transcriptional activity) the polymerase is clearly
not pure (Fig. 4, lane 1). The purity achieved is comparable to that
of recent attempts using His-tagged proteins expressed in
Pichia pastoris (58) or baculovirus systems (59). However,
neither of these systems displays appreciable levels of tran-
scription initiation in the absence of an added primer, which
precludes their use for the enzymatic analyses of 5′ end
structure reported here. In addition, the affinity selection
system permits the analysis of wild-type, non-tagged polymerase.
Efficient binding to the 5′ end of vRNA was shown to be
dependent on the formation of a complex between PB1 and
PA, with or without the inclusion of PB2. No binding was
observed for PB1 alone using either a gel shift assay or SA-bead
immobilised 5′-vRNA sequences. This is in contrast to what
has been observed using co-immunoprecipitation assays and
northwestern blotting where binding of PB1 alone has been clearly
demonstrated (51). This discrepancy is not due to differences
between the A/PR/8/34 and A/Victoria/72 virus strains used in the
two studies, because we find that the A/PR/8/34 PB1 protein is
capable of binding 5′-terminal sequences in northwestern blot
experiments (E.Medcalf and P.Digard, unpublished experiments).
However, it may arise from differences between the assay
systems used. One possibility is that PA increases the affinity
of PB1 for 5′-terminal sequences, and that in our system, the
concentration of PB1 is too low to detect binding in the
absence of PA. The estimated apparent Kd for the PB1–5′ end
interaction is ∼2 × 10–8 M (51) and this is slightly lower than
the concentration of PB1 we estimate to be present in our
binding reactions (∼8 × 10–8 M). One would therefore expect to
see some binding of PB1 alone to the immobilised 5′-vRNA
oligonucleotide. However, the estimates of PB1 concentration
in both studies are subject to a significant degree of error, and
furthermore, it is possible that the proportion of functional PB1
in the extracts varies from one preparation to another. The
finding that PA is necessary for a stable interaction with the
5′ end of vRNA under the conditions used here could be
explained by a chaperone effect on PB1, or alternatively by a
PA–RNA interaction that increases the avidity of the protein–RNA
interaction. The latter possibility is consistent with earlier work
that showed PA could be UV cross-linked to a radiolabelled
5′-vRNA molecule (46).
The purified 3P complex was transcriptionally active when
bound to the immobilised 5′ vRNA sequence, and could
perform ApG, capped mRNA-primed and unprimed synthesis
of a 34 nt template RNA. The PB1/PA complex had no
measurable transcriptase activity (at least under the current
conditions of the assay). Thus, PB2 was essential for the
formation of a transcriptionally active complex. However,
NP was not necessary for any of these activities. In a cellular
environment, NP is essential for viral RNA gene expression (1)
and  in vitro studies based on authentic viral RNPs have
suggested at least two mechanisms to explain this dependency.Nucleic Acids Research, 2002, Vol. 30, No. 2   437
Removal of NP from RNPs by treatment with high salt concentra-
tions left polymerase–RNA complexes that were able to initiate
ApG primed transcription but were unable to synthesise full-
length products (60). Thus, it was suggested that NP acts as a
processivity factor for the polymerase. In our recombinant
system, NP is clearly not essential for transcription of 34 or 53 nt
templates (Fig. 5 and data not shown). Experiments are in
progress to determine if longer templates can also be used in
the absence of NP. Another identified role for NP in transcrip-
tion is during replicative transcription. RNP complexes from
infected cells will synthesise c- and vRNA in vitro, but only in
the presence of non-RNP associated NP. In the case of cRNA
synthesis, free NP was shown to be necessary for readthrough
of the polyadenylation signal, and for vRNA synthesis, it was
required for the production of full-length transcripts (33,34).
However, technical limitations prevented examination of the
role of NP in the initiation of unprimed transcription and of the
nature of the 5′-terminal groups of the in vitro synthesised
c- and vRNA molecules (34). We show here, for the first time,
unambiguous in vitro transcription initiation in the absence of
NP and added primers to produce an RNA molecule with a
5′ di- or triphosphate group (Fig. 6). This suggests that the role
of NP in the switch from mRNA to replicative synthesis is not
a direct effect on the ability of the polymerase to initiate
unprimed synthesis. It has been proposed that NP must co-
transcriptionally encapsidate the nascent RNA for the
polymerase to continue to replicate its template RNA (34). The
34 nt template used in this present study may be too short to
reveal such a requirement. One other mechanism for
NP control of replication is its possible role in the shift from
pan handle to linear conformations of the template RNA. In the
pan handle conformation, the polymerase is able to bind to 5′
and 3′ ends simultaneously, whereas in the linear conformation
it must first bind to the 5′ end alone before subsequently inter-
acting with the 3′ end of the same or different template RNA.
This latter scenario is analogous to the assembly steps
followed in the bead assay in its current form. It will be inter-
esting to test in future whether the initial conformation of the
template RNA affects the different transcriptional activities of
the polymerase and whether NP exerts any influence upon this.
ApG primed synthesis gave rise to a predominant 14 nt
premature termination product (with lesser amounts of smaller
products) that was absent from globin mRNA primed
synthesis. These products appear to be distinct from those
reported previously (29) in that their synthesis is clearly
template-dependent and they are smaller (ranging from 11 to
14 nt, compared to the 15–21 nt  template-independent products
reported previously). This previous study used micrococcal
nuclease treated viral cores as the source of polymerase that
undoubtedly contains residual degraded 5′ and 3′ template
sequences that could give rise to such products. This is not the
case with the vaccinia-expressed polymerase used in this present
study. The cause or significance of these presumed premature
termination products is not known. However, the region where
termination occurs corresponds to the clamp region of the puta-
tive RNA fork that is important for the association between the
5′ and 3′ ends (54). Possibly the polymerase struggles to
disrupt this base paired region, and this results in product and/or
template release. Lack of premature termination for the cap-
primed reactions may reflect the more stable association of the
product RNA with the polymerase due to binding to the cap
structure. Alternatively it may reflect a cap induced conforma-
tional change in the polymerase (akin to the allosteric modula-
tion effect where ApG primed synthesis is increased as a result
of occupation of the cap-binding site by a cap analogue) (61)
whereby the polymerase no longer terminates prematurely.
The assay reported here is a significant advance for studying
the activities of the viral polymerase. In particular it offers
tremendous potential for studying the various stages of the
transcription process. Because the influenza polymerase does
not release from the bead during transcription it is possible to
manipulate the reaction conditions sequentially by exchanging
the composition of the transcription buffer. By using subsets of
nucleotides the polymerase can be ‘walked’ to defined points
along its template to study its behaviour as it encounters
putative signals at different stages of the transcription process,
e.g. initiation, cap release, termination and polyadenylation.
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